| abstract |
Cells in liver tumor masses contain a unique set of protein / tumor antigens as compared to normal hepatocyte epithelial cells implanted in the tumor. The presence of tumor antigens is associated with the production of autoantibodies to these tumor antigens. The present invention relates to identification and identification of a set of proteins that can serve as a new marker set for liver cancer diagnosis and prediction. Specifically, the present invention relates to a kit which enables diagnostic and prognostic measurement of autoantibodies in serum of patients with liver cancer. In order to complement the conventional diagnostic method, the present invention provides a method for screening for IL-17, IL-17, IL-17, IL-17, or IL26 in combination with Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, Specific, sensitive, cost-effective detection and quantification method by evaluating a set of certified liver cancer protein / tumor antigens, including, but not limited to, |